Tasly Pharmaceutical Group Future Growth

Future criteria checks 1/6

Tasly Pharmaceutical Group is forecast to grow earnings and revenue by 11.9% and 6.2% per annum respectively. EPS is expected to grow by 11.7% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

11.9%

Earnings growth rate

11.7%

EPS growth rate

Pharmaceuticals earnings growth	18.6%
Revenue growth rate	6.2%
Future return on equity	10.2%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Earnings and Revenue Growth Forecasts

SHSE:600535 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10,113	1,492	N/A	2,154	5
12/31/2025	9,962	1,438	N/A	1,612	7
12/31/2024	9,073	1,174	N/A	1,692	3
3/31/2024	8,638	1,102	1,551	2,088	N/A
12/31/2023	8,674	1,071	1,907	2,576	N/A
9/30/2023	9,032	1,120	1,775	2,293	N/A
6/30/2023	8,951	867	1,956	2,502	N/A
3/31/2023	8,798	567	1,792	2,351	N/A
12/31/2022	8,637	-264	1,875	2,280	N/A
9/30/2022	8,315	534	1,313	1,803	N/A
6/30/2022	8,159	940	1,356	1,782	N/A
3/31/2022	8,063	1,478	1,964	2,480	N/A
12/31/2021	7,952	2,359	2,229	2,801	N/A
9/30/2021	7,955	1,507	2,249	2,739	N/A
6/30/2021	8,779	1,442	1,615	2,145	N/A
3/31/2021	11,387	1,154	1,736	2,163	N/A
12/31/2020	13,576	1,126	1,382	1,791	N/A
9/30/2020	16,298	969	966	1,550	N/A
6/30/2020	18,205	789	1,467	2,102	N/A
3/31/2020	18,380	848	764	1,455	N/A
12/31/2019	18,998	1,001	949	1,680	N/A
9/30/2019	19,057	1,308	770	1,597	N/A
6/30/2019	18,931	1,519	875	1,718	N/A
3/31/2019	18,609	1,622	796	1,601	N/A
12/31/2018	17,990	1,545	714	1,494	N/A
9/30/2018	17,957	1,607	907	1,432	N/A
6/30/2018	17,306	1,545	536	1,023	N/A
3/31/2018	16,699	1,430	-442	75	N/A
12/31/2017	16,094	1,377	N/A	-796	N/A
9/30/2017	15,497	1,312	N/A	-637	N/A
6/30/2017	14,811	1,248	N/A	-692	N/A
3/31/2017	14,148	1,218	N/A	298	N/A
12/31/2016	13,945	1,176	N/A	1,154	N/A
9/30/2016	13,454	1,263	N/A	759	N/A
6/30/2016	13,391	1,333	N/A	840	N/A
3/31/2016	13,294	1,410	N/A	502	N/A
12/31/2015	13,228	1,479	N/A	340	N/A
9/30/2015	12,742	1,447	N/A	351	N/A
6/30/2015	12,698	1,454	N/A	326	N/A
3/31/2015	12,640	1,429	N/A	326	N/A
12/31/2014	12,578	1,368	N/A	617	N/A
9/30/2014	12,234	1,335	N/A	810	N/A
6/30/2014	11,816	1,242	N/A	602	N/A
3/31/2014	11,394	1,138	N/A	480	N/A
12/31/2013	11,108	1,098	N/A	345	N/A
9/30/2013	10,942	1,060	N/A	122	N/A
6/30/2013	10,554	1,005	N/A	342	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600535's forecast earnings growth (11.9% per year) is above the savings rate (2.9%).

Earnings vs Market: 600535's earnings (11.9% per year) are forecast to grow slower than the CN market (24.4% per year).

High Growth Earnings: 600535's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600535's revenue (6.2% per year) is forecast to grow slower than the CN market (14.6% per year).

High Growth Revenue: 600535's revenue (6.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600535's Return on Equity is forecast to be low in 3 years time (10.2%).

Tasly Pharmaceutical Group Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased by 7.0% to CN¥13.88

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Consensus EPS estimates increase by 12%

Price target increased by 9.3% to CN¥12.10

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Earnings beat expectations, revenue disappoints

New 90-day high - CN¥19.62

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies